# Children's Hospital and Health System Chorus Community Health Plans (CCHP) Policy and Procedure

This policy applies to the following entity(s):  CHW – Milwaukee  CHHS Foundation  CHW – Community Services Division  Children's Medical Group - Primary Care  Children's Medical Group - Urgent Care	CHW - Fox Valley CHW - Surgicenter Chorus Community Health Plans Children's Specialty Group CHHS Corporate Departments	
Medical Utilization Management Policy		
SUBJECT: CONTINUOUS GLUCOSE MONITORING DEVICES		

# **INCLUDED PRODUCT(S):**

Medicaid	Individual and Family
BadgerCare Plus     BadgerCare Plus	
☐ Care4Kids Program	⊠ Marketplace

#### **PURPOSE OR DESCRIPTION:**

The purpose of this policy is to define criteria for the medically necessary use of continuous glucose monitoring (CGM) devices.

### **POLICY:**

Continuous glucose monitoring may be indicated for **1 or more** of the following:

- 1. Type 1 or type 2 diabetes mellitus, and long-term continuous glucose monitoring needed, as indicated by **ALL** of the following:
  - a. Intensive insulin regimen (3 or more insulin injections per day, or use of continuous subcutaneous insulin infusion pump)
  - Patient (or parent/guardian/caregiver if patient is a minor) is motivated and knowledgeable about use of continuous glucose monitoring, is adherent to diabetic treatment plan, and participates in ongoing education and support
- 2. Type 1 or type 2 diabetes mellitus, and short-term continuous glucose monitoring needed, as indicated by **ALL** of the following:

Effective: 3/22 Revised: 9/23 Last reviewed: 9/23

Q:\CCHP Leadership\Utilization Management Medical Policies\APPROVED MEDICAL UM POLICIES

Developed by: CCHP Medical Directors

- Additional information about blood glucose needed, as indicated by 1 or more of the following:
  - i. Dawn phenomenon, known or suspected
  - ii. Hypoglycemic unawareness (i.e. memberdoes not have symptoms with hypoglycemia)
  - iii. Nocturnal hypoglycemia, known or suspected
  - iv. Postprandial hyperglycemia, known or suspected
  - v. Significant change to diabetes treatment regimen (i.e. initiation of insulin, change from multiple-dose insulin to insulin pump)
  - vi. Unexplained hyperglycemia
- b. Monitoring limited to 3-14 days

For all other uses, CCHP considers continuous glucose monitoring NOT medically necessary.

As the lifespan of a CGM receiver is expected to be at least three years, CCHP will replace a CGM receiver if three or more years have passed since the last receiver was dispensed.

## **REFERENCES**

- 1. Centers for Medicare and Medicaid Services, Ruling No. CMS-1286-R. 12 January 2017, www.cms.gov/regulations-and-guidance/guidance/rulings
- 2. ForwardHealth Update No 2021-53, Expanded Coverage for Personal Continuous Glucose Monitoring Devices and Accessories, December 2021
- 3. Hayes Health Technology Assessment, Continuous Glucose Monitoring Systems, October 2019, Copyright © 2022 Hayes, LLC
  - See references from Hayes Technology Assessment
- 4. MCG Guideline ACG: A-126 (AC), Continuous Glucose Monitoring (CGM); MCG Health, Ambulatory Care 25rd Edition, Copyright © 2022 MCG Health, LLC
  - See references from MCG Guideline

Effective: 3/22 Revised: 9/23 Last reviewed: 9/23